Brooks Laboratories Ltd

At Rs 63.00, Brooks Laboratories Ltd found itself trapped at its lower circuit on 24 Jul 2026, with a 4.52% decline marking the maximum loss permitted by the 5% price band. Despite sellers lining up to exit, there were no buyers willing to absorb the supply, resulting in a frozen price and unfilled sell orders throughout the session.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Brooks Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 8 July 2026, driven primarily by a significant improvement in its valuation metrics. Despite persistent challenges in financial performance and technical indicators, the company’s valuation grade has shifted from fair to very attractive, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Brooks Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant shift in its valuation parameters, moving from a fair to a very attractive rating. Despite recent share price declines and underperformance relative to the Sensex, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling entry points compared to both its historical averages and peer group valuations.

At Rs 69.52, Brooks Laboratories Ltd found itself locked at its lower circuit limit of 4.81% on 08 Jul 2026, with persistent selling pressure overwhelming demand and leaving unfilled supply at the floor price.

At Rs 73.03, sellers were still queuing — but there were no buyers willing to take the other side. Brooks Laboratories Ltd locked at its lower circuit of 5.0% on 7 Jul 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock with limited liquidity.

Brooks Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 6 July 2026. The revision reflects a deterioration in valuation metrics, financial trends, and technical indicators, despite some pockets of fair valuation and moderate profitability. This comprehensive analysis explores the four key parameters that triggered the rating change and what it means for investors.

At Rs 75.91, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 4.99% on 2 Jul 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 72.3, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5.0% on 1 Jul 2026, with buyers queuing and no sellers willing to part with shares.

Brooks Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 June 2026, driven primarily by a marked improvement in valuation metrics. Despite ongoing challenges in financial performance and technical indicators, the company’s valuation has become very attractive relative to its peers, prompting a reassessment of its investment appeal.

Brooks Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to a very attractive rating, despite ongoing sector headwinds and a challenging price performance relative to the broader market. This repositioning is driven primarily by its low price-to-earnings (P/E) and price-to-book value (P/BV) ratios, which now stand significantly below peer averages, signalling potential value for discerning investors.

At Rs 69.88, sellers were still queuing — but there were no buyers willing to take the other side. Brooks Laboratories Ltd locked at its lower circuit of 5% on 29 Jun 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

At Rs 74.5, Brooks Laboratories Ltd found itself locked at its lower circuit limit of 2.99% on 25 Jun 2026, with sellers lined up but no buyers willing to absorb the supply. The 5% price band capped the daily loss, yet the unfilled sell orders highlight persistent selling pressure and a frozen price environment.

Brooks Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 23 June 2026, reflecting deteriorating fundamentals and valuation concerns. Despite a recent uptick in share price, the micro-cap pharmaceutical company faces challenges across quality, valuation, financial trends, and technical indicators, prompting a reassessment of its investment appeal.

Brooks Laboratories Ltd has experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change reflects evolving market perceptions and comparative metrics within the Pharmaceuticals & Biotechnology sector, prompting investors to reassess the stock’s price attractiveness amid broader industry and market dynamics.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 73.51, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5.0% on 23 Jun 2026, with buyers queuing and no sellers willing to part with shares.